Key result
Carotid plaque echolucency is not associated with 30-day neurological complications after carotid artery stenting.
Why the study?
Plaque characteristics are suggested to be important risk factors for poor outcome after carotid artery stenting, but their association with neurological complications is unclear.
Does plaque echolucency predict 30-day neurological complications in patients undergoing elective carotid artery stenting?
Cohort (n=698)
No
Does plaque echolucency predict 30-day neurological complications in patients undergoing elective carotid artery stenting?
p-value: p=>0.05
Plaque echolucency measured by objective and subjective grading does not identify patients at increased risk of peri-interventional neurological events during carotid stenting and cannot be recommended for risk stratification.
Does not support echolucency scoring for pre-stenting risk stratification; leaves open whether other plaque features predict periprocedural stroke.
Background and Purpose— Plaque characteristics are suggested to play a potentially important role as risk factors for poor outcome after carotid artery stenting (CAS). We therefore correlated objectively and subjectively determined carotid plaque morphology with neurological complications after CAS. Methods— We enrolled 698 consecutive patients undergoing elective CAS from a prospective single-center registry database and classified the preinterventional plaque status according to gray-scale median levels and the standardized Beletsky and Gray-Weale plaque scores. Patients were followed for 30-day neurological complications. Results— Neurological complications including transient ischemic attack, minor and major stroke occurred in 5.9% (41/698) of the patients. Median gray-scale median, Beletsky and Gray-Weale scores were 45 (interquartile range [IQR] 25 to 70), 3.0 (IQR 2.0 to 3.0) and 2.0 (IQR 2.0 to 3.0), respectively. None of the scores was significantly associated with adverse outcome adjusting for traditional risk factors, medication, preinterventional symptoms, degree of stenosis, contralateral occlusion and use of cerebral protection, neither with respect to all neurological complications nor with respect to stroke and death (all P >0.05). Conclusions— Plaque echolucency measured by objective and subjective grading did not identify patients with an increased risk of peri-interventional neurological events. Evaluation of plaque echolucency therefore cannot be recommended for risk stratification in CAS patients.
No takes yet. Share an insight, caveat, or question.
Reiter et al. (2006) conducted a cohort in Elective carotid artery stenting (n=698). Plaque echolucency (gray-scale median levels, Beletsky and Gray-Weale scores) was evaluated on 30-day neurological complications including transient ischemic attack, minor and major stroke (p=>0.05). Preinterventional carotid plaque echolucency was not significantly associated with 30-day neurological complications, stroke, or death following elective carotid artery stenting (P>0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: